Market Place
Sourcing Support
Propanc`s Proenzymes Cancer Treatment Articles Generate Interest
21 Aug 2024 //
BUSINESSWIRE
Propanc Biopharma Receives Patent Notice For "Proenzyme Composition" In America
14 Aug 2024 //
BUSINESSWIRE
Propanc`s CSO Predicts PRP May Boost Immune Checkpoint Inhibitors
17 Jul 2024 //
BUSINESSWIRE
Propanc Biopharma Receives Patent Grant for “Proenzymes Composition” from Japan
25 Jun 2024 //
BUSINESSWIRE
Propanc Granted EU Proenzyme Cancer Treatment Composition Patent
16 Apr 2024 //
BUSINESSWIRE
Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment
08 Apr 2024 //
BUSINESSWIRE
Propanc to Host Call Highlighting Positive Results from Compassionate Use Study
22 Feb 2024 //
BUSINESSWIRE
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent
16 Jan 2024 //
BUSINESSWIRE
Propanc Engages Advisory Firm to Identify Strategic Investment Opportunities
18 Dec 2023 //
BUSINESSWIRE
Propanc’s Partner Pushing Boundaries to Circumvent Chemotherapy Resistance
13 Dec 2023 //
BUSINESSWIRE
Propanc Biopharma Confirms PRP Enhances Chemosensitivity
07 Nov 2023 //
BUSINESSWIRE
Propanc Biopharma Targets Site of First-In-Human Study for PRP
15 Aug 2023 //
BUSINESSWIRE
Propanc’s Clinical Candidate PRP Market Forecast to Reach $6.93 Billion by 2030
25 Jul 2023 //
BUSINESSWIRE
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
13 Jul 2023 //
BUSINESSWIRE
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy
05 Jul 2023 //
BUSINESSWIRE
Propanc Biopharma’s Intellectual Property Portfolio Makes Advancements in Europe
25 May 2023 //
BUSINESSWIRE
Propanc Biopharma’s Intellectual Property Portfolio Achieves Milestones
23 May 2023 //
BUSINESSWIRE
Propanc Biopharma Announces Reverse Stock Split
22 May 2023 //
BUSINESSWIRE
Propanc Announces That PRP Suppresses TGF-? Pathway & Tumor Microenvironment
28 Mar 2023 //
BUSINESSWIRE
Propanc Confirm PRP Exerts Effects Against Chemoresistant Pancreatic Tumor Cells
16 Mar 2023 //
BUSINESSWIRE
Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the EORTC
11 Jan 2023 //
BUSINESSWIRE
Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference
15 Dec 2022 //
BUSINESSWIRE
Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent
30 Nov 2022 //
BUSINESSWIRE
Propanc’s CSO Predicts PRP Enhance Effects of Immune Checkpoint Therapy
15 Nov 2022 //
BUSINESSWIRE
Propanc Biopharma’s CEO to Attend 43rd Meeting of the EORTC, Dec 15 - 17
12 Oct 2022 //
BUSINESSWIRE
Propanc Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies
29 Sep 2022 //
BUSINESSWIRE
Propanc Biopharma Provides Shareholder Update
13 Sep 2022 //
BUSINESSWIRE
Propanc Reports Significant Effects of PRP Against the Tumor Microenvironment
08 Sep 2022 //
BUSINESSWIRE
Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen
23 Aug 2022 //
BUSINESSWIRE
Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions
16 Aug 2022 //
BUSINESSWIRE
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects
28 Jul 2022 //
BUSINESSWIRE
Propanc Biopharma Produces Synthetic Recombinant Trypsinogen Via POP1 Program
19 Jul 2022 //
BUSINESSWIRE
Propanc’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I
12 Jul 2022 //
BUSINESSWIRE
Propanc’s CEO Comments on the 39 Granted Patents and 26 Patent Applications
05 Jul 2022 //
BUSINESSWIRE
Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split
24 Jun 2022 //
BUSINESSWIRE
Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results
22 Jun 2022 //
BUSINESSWIRE
Propanc Biopharma’s PRP to Target 80 – 90% of Cancer Cases
14 Jun 2022 //
BUSINESSWIRE
Propanc Biopharma Presents Evidence for “Novel” Enzyme Therapeutic Approach
26 May 2022 //
BUSINESSWIRE
Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use
18 May 2022 //
BUSINESSWIRE
Propanc Biopharma Offers a Novel Way to Stop Cancer
11 May 2022 //
BUSINESSWIRE
Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture
02 May 2022 //
BUSINESSWIRE
Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care
06 Apr 2022 //
BUSINESSWIRE
Propanc Receives Notice of Allowance for Method to Treat Cancer Stem Cells
22 Mar 2022 //
BUSINESSWIRE
Propanc’s CEO Believes Proenzyme Therapy Mightbe the Healthcare Solution
16 Mar 2022 //
BUSINESSWIRE
Propanc Biopharma’s Cancer Stem Cell Technology Against Metastatic Cancer
02 Mar 2022 //
BUSINESSWIRE
Propanc’s Joint Research Partnership with Universities of Jaén and Granada
23 Feb 2022 //
BUSINESSWIRE
Propanc Biopharma Enters into $5M Equity Purchase Facility
14 Dec 2021 //
BUSINESSWIRE
Propanc Biopharma Appoints Paul Patrizio as Strategic AdvisorUS Based
03 Nov 2021 //
BUSINESSWIRE
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy
18 Jan 2021 //
BUSINESSWIRE
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy
18 Jan 2021 //
BIOSPACE
Propanc Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid
11 Jan 2021 //
BUSINESSWIRE
Propanc Biopharma Receives First Granted Patent for Method
21 Dec 2020 //
BUSINESSWIRE
Propanc Receives First Granted Patent for Method to Treat Cancer Stem Cells
21 Dec 2020 //
BUSINESSWIRE
Propanc Biopharma Provides Shareholder Update
14 Dec 2020 //
BUSINESSWIRE
Propanc Biopharma Receives Investment from Institutional Investor
27 Jul 2020 //
BUSINESSWIRE
Propanc Biopharma Receives First Allowance for Key Patent Family Patent Office
14 Apr 2020 //
BUSINESSWIRE
Propanc Biopharma Illustrates Novel Mode of Action of PRP
21 Oct 2019 //
BUSINESSWIRE
Propanc Initiates Dev of Bio-Analytical Assay in Preparation for Human Trials
25 Mar 2019 //
PR NEWSWIRE
Propanc`s Receives Notice of Allowance-Claims from Foundation Patent in the U.S.
13 Mar 2019 //
PR NEWSWRE
